




RealRate

PHARMACEUTICAL 2023

uniQure N.V.
Rank 160 of 446

uniQure





PHARMACEUTICAL 2023

uniQure N.V.
Rank 160 of 446

uniQure

The relative strengths and weaknesses of uniQure N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of uniQure N.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 39% points. The greatest weakness of uniQure N.V. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	476,774
Cost of Goods Sold	1,254
Intangible Assets	84,359
Liabilities, Current	75,919
Liabilities, Non-Current	153,036
Other Assets	93,299
Other Compr. Net Income	-29,435
Other Expenses	13,143
Other Liabilities	0
Other Net Income	26,604
Other Revenues	113,654
Property and Equipment	50,532
Research and Development	197,591
Selling, General and Administrative Expense	55,059

Output Variable	Value in 1000 USD
Assets	704,964
Liabilities	228,955
Expenses	267,047
Revenues	113,654
Stockholders Equity	476,009
Net Income	-126,789
Comprehensive Net Income	-141,506
Economic Capital Ratio	145%